Community Practice Connections™ 18th Annual Winter Lung Cancer Conference®

Release Date: March 31, 2021
Expiration Date: March 31, 2022

Activity Overview

Therapy of patients with thoracic malignancies continues to advance on several fronts, including treatment of earlier disease stages and development of new agents. Lung cancer is comprised of multiple disease subsets that are characterized by distinct histologic and molecular markers. Targeting these characteristics defines how personalized care strategies should be applied in the management of patients with these tumors. Classification of lung cancers continues to evolve as basic science advances. Our understanding of resistance mechanisms and immune pathways (such as immune checkpoints) has expanded treatment options for patients with advanced forms of lung cancer. Many of these strategies are either utilized or being assessed in clinical trials in multiple lines of care.

This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the 18th Annual Winter Lung Cancer Conference^®, held in February 2021. This unique and engaging multi-media activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with lung cancer, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca; BeiGene, Ltd; Bristol Myers Squibb; Daiichi Sankyo, Inc; Jazz Pharmaceuticals, Inc; Lilly; Novartis Pharmaceuticals Corporation; Pfizer Inc; and Takeda Oncology.

Target Audience

This educational activity is directed toward oncologists involved in the treatment of patients with lung cancers. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, fellows, and other health care professionals interested in the treatment of lung cancers may also participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Integrate molecular testing strategies to inform treatment selection in patients with oncogene-driven non–small cell lung cancer (NSCLC)
• Evaluate emerging approaches to patient selection for immunotherapy and targeted agents
• Assess treatment strategies for early-stage and locally advanced lung cancer
• Describe the use of cytotoxic, targeted, and other systemic agents in the management of patients with lung cancer with or without oncogenic drivers
• Incorporate immunotherapeutic strategies in patients with thoracic malignancies along the disease continuum
• Discuss approaches to mitigate and manage treatment-related adverse events in patients with lung cancer

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Faculty

Julie R. Brahmer, MD, MSc, FASCO
Director, Thoracic Oncology Program
Professor of Oncology
Johns Hopkins Kimmel Cancer Center
Baltimore, MD

Disclosures: Grant Research Support: AstraZeneca, Bristol Myers Squibb, Genentech/Roche, Eli Lilly and Company, RAPT Therapeutics, Inc, Revolution Medicines; Consultant: Amgen, Bristol Myers Squibb (uncompensated), Eli Lilly and Company, Genentech/Roche, GlaxoSmithKline, Eli Lilly and Company, Sanofi, Regeneron; Other: Data and safety monitoring board: Incyte, Takeda, University of Pennsylvanai.

Rogerio C. Lilenbaum, MD
Director
Banner MD Anderson Cancer Center
Phoenix, AZ

Disclosures: Consultant: AstraZeneca.

Mark A. Socinski, MD
Executive Medical Director
AdventHealth Cancer Institute
Member, Thoracic Oncology Program
Orlando, FL

Disclosures: Grant Research Support: Celgene, Genentech, Synta, Pfizer, BMS, Novartis, Spectyrum; Speakers Bureau: AstraZeneca, , Blueprint, Bristol Myers Squibb, Genentech, Jazz, Novartis.

Lecia V. Sequist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Mary B. Saltonstall Endowed Chair in Oncology
Massachusetts General Hospital
Boston, MA

Disclosures: Grant Research Support: Novartis, AstraZeneca, Genentech, Boehringer Ingelheim; Consultant: AstraZeneca, Genentech, Janssen.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.